US 2002/0177556 A1Published application

Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists

AssigneeAEterna Zentaris GmbH

InventorsJurgen Engel, Rainer Voegeli

Life of this patent

Estimating the term…

Abstract

The present invention relates to the treatment of dementia and neurodegenerative diseases like Alzheimer's disease with intermediate doses of LHRH antagonists which do not cause a castration. A preferred LHRH antagonist is cetrorelix.

Claims13

Dependent claims

A method of treating one or more of dementia and neurodegenerative diseases in humans comprising the administration of an effective dose of a LHRH antagonist.

Dependencies are inferred from the claim text.

Facts

Application: 10/133,967Filed 27 Apr 2002
Priority: 30 Apr 2001
Published: 28 Nov 2002
Term ends: Not estimatedThe source records don’t support an estimate.

Classification5 codes

A61K 38/09
Peptides having 5 to 11 amino acids: luteinising hormone-releasing hormone [LHRH] , i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
A61P 25/00
Drugs for disorders of the nervous system
A61P 25/28
Drugs for disorders of the nervous system: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents,…
A61K
Medicines and medical preparations

Family

Application60/287,434Us provisional application · filed 30 Apr 2001
US 7,288,517 B2Related patent
US 2002/0177556 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results